Aurobindo Pharma's ANDA for Canagliflozin Receives Approval Status
Aurobindo Pharma's ANDA210386 for Canagliflozin has received an approval status (AP) from the FDA.
Asset / Drug
Drug and asset intelligence for Canagliflozin with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
SGLT2 Inhibitor
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.